Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky join the Supervisory Board of 4SC AG
Since 2006, Prof. Dr. Rübsamen-Schaeff has acted as Managing Director and CEO of AiCuris GmbH, a German biopharma company founded by her. In this capacity, she was responsible, among other things, for securing a licensing deal with US pharmaceutical company Merck with a total value of up to EUR 442 million plus royalties. From 1994 to 2006 she held senior research positions at Bayer AG, Leverkusen, first as Vice President and Head of Antiviral Research from 1994 to 2001, later as Senior Vice President and Global Head of Bayer's Anti-Infective Research. After obtaining a degree and doctorate in chemistry and working as a guest scientist at various international institutions including the US-universities Harvard and Cornell, she was Scientific and Managing Director at the Institute of Biomedical Research Georg-Speyer-Haus in Frankfurt (now Institute for Tumor Biology and Experimental Therapy) for six years. In 1988 she was appointed as Professor of Biochemistry and Virology at the University of Frankfurt. In 2014 she was appointed as member of the Board of Partners and of the Supervisory Board of German pharmaceutical and chemical group Merck KGaA, Darmstadt, also acting as Chair of the company's Research Council since then.
Joerg von Petrikowsky has more than 30 years of experience as an auditor and tax adviser focusing in particular on the auditing and advising of international pharmaceutical, medical technology and biotechnology companies. Working for Arthur Andersen (1984-2002) and Ernst & Young (2002-2013), he held various senior positions including Head of Life Sciences at Ernst & Young. On the Supervisory Board of 4SC, Mr. von Petrikowsky will act as Chairman of the Audit Committee and as the independent financial expert.
Both terms of office will initially run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for the financial year 2014. Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn who recently stepped down. Thus the Supervisory Board of 4SC AG chaired by Dr. Clemens Doppler again consists of six members.
Dr. Clemens Doppler, Chairman of the Supervisory Board of 4SC AG, comments: "We are very pleased that with Helga Rübsamen-Schaeff and Joerg von Petrikowsky we have been able to attract two highly competent and renowned individuals for the Supervisory Board of 4SC AG."
Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.
4SC discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 65 employees (55 FTEs) at 30 September 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005 (ISIN DE0005753818).